NeuroVive signs collaboration agreement with Isomerase Therapeutics and receives the first milestone payment from Sihuan

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from Biotica. In addition, the company´s Asian subsidiary has received the first milestone payment from Sihuan Pharmaceutical, the company´s collaboration partner in China.The collaboration agreement with Isomerase TherapeuticsNeuroVive has signed a collaboration agreement with the British firm Isomerase Therapeutics Ltd. for the product development and commercialization of the cyclophilin-